dipyridamole / Generic mfg. - LARVOL DELTA

Dipyridamole Ameliorates Memory Impairment and Increases Hippocampal Calbindin Expression in Niemann Pick C1 Mice. (PubMed, J Neurosci Res) - "Currently, miglustat is the only approved drug for NPC1, thus the identification of new treatments is mandatory. Our results demonstrated that DIP selectively ameliorates the cognitive impairment in NPC1 mice. This drug could thus represent a valuable therapeutic tool to be used in combination with other treatments in NPC1."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • CALB1

Topical Application of Dipyridamole and Roflumilast Combination Nanoparticles Loaded Nanoemulgel for the Treatment of Psoriasis in Rats. (PubMed, Int J Nanomedicine) - "The aim was to evaluate the anti-psoriatic effect of the topical administration of dipyridamole and roflumilast nanoemulgel combination on imiquimod-induced psoriasiform skin inflammation in rats. DR-NEG showed a significantly lower PASI and Baker score than the clobetasol group. The new DR-NEG's topical combination administration showed better anti-inflammatory, tissue healing, and anti-psoriatic activity than each drug alone or topical clobetasol administration; this could be attributed to the possible synergic effects of both drugs and the enhanced skin penetration offered by the nanoemulgel formulation."

Journal • Preclinical • Dermatitis • Dermatology • Immunology • Inflammation • Psoriasis • IL17A • TGFB1 • TNFA

The Greening of Hair: A Unique Case of Chlorotrichosis and Its Management. (PubMed, Skin Appendage Disord) - "Various factors, including occupational copper exposure and serum extravasation containing dipyridamole, have been associated with green hair. Treatment options encompass the use of EDTA-containing shampoos, among others. Dermatologists should be knowledgeable about its causes, predisposing factors, and effective management to enhance the diagnosis and treatment of this distinctive hair disorder."

Journal • Dermatology

Characterization of dipyridamole as a novel ferroptosis inhibitor and its therapeutic potential in acute respiratory distress syndrome management. (PubMed, Theranostics) - "Notably, the clinical trial further corroborated the therapeutic potential of DIPY in ARDS patients, demonstrating improved outcomes with DIPY adjunctive therapy. These findings provide compelling evidence that DIPY inhibits ferroptosis in pulmonary epithelial and endothelial cells by modulating the SOD1/CREB1/HMOX1 signaling axis and suggest DIPY as a promising therapeutic strategy for ARDS treatment."

Journal • Acute Lung Injury • Acute Respiratory Distress Syndrome • Infectious Disease • Inflammation • Pulmonary Disease • Respiratory Diseases • Septic Shock • Targeted Protein Degradation • CREB1 • HMOX1 • SOD1

Acute treatment and secondary prevention for patients with minor stroke or transient ischemic attack: A Bayesian network meta-analysis. (PubMed, Eur Stroke J) - "Dipyridamole + aspirin resulted in the lowest risk of bleeding. In MSs, compared to IVT, DAPT may be associated with better improvements in neurological function, and it may not increase the risk of bleeding."

Journal • Retrospective data • Review • Cardiovascular • Cerebral Hemorrhage • Hematological Disorders • Ischemic stroke

Absence of long-term incremental prognostic value of inducible wall motion abnormalities on dipyridamole stress CMR in patients with suspected or known coronary artery disease. (PubMed, Eur Radiol) - "Question The long-term incremental prognostic value of inducible wall motion abnormalities by stress cardiac MR in patients with known or suspected CAD requires investigation. Findings The presence of inducible wall motion abnormalities did not offer additional prognostic value in comparison to the only reversible perfusion defect. Clinical relevance Independent from the presence of wall motion abnormalities, more aggressive management may be appropriate in patients with reversible perfusion defects to reduce the long-term risk of cardiovascular events."

Journal • Cardiovascular • Coronary Artery Disease • Diabetes • Metabolic Disorders • Myocardial Infarction

3D-printing of dipyridamole/thermoplastic polyurethane materials for bone regeneration. (PubMed, Drug Deliv Transl Res) - "These promising results suggest that DIP-loaded TPU-based scaffolds may enhance bone regeneration. Combined with the flexibility of 3D printing, this approach has the potential to enable the creation of customized scaffolds tailored to patients' needs at the point of care in the future."

Journal

Evaluation of aspartame as a co-former in the preparation of co-amorphous formulations of dipyridamole using spray drying. (PubMed, Int J Pharm) - "To predict stability under accelerated conditions, the crystallization rates from DPM-AspPhe were fitted to a modified Arrhenius equation. However, the predictive accuracy of the resulting model was limited to a specific range of conditions."

Journal

Efficacy and safety of edaravone combined with Ginkgo Leaf Extract and Dipyridamole in the treatment of acute cerebral infarction: A systematic review and meta-analysis. (PubMed, Medicine (Baltimore)) - "The combination of edaravone with GLED for treating ACI has better efficacy and higher safety than edaravone alone. Given the limited number of studies identified and possibility of publication bias, the above findings should be verified by more high-quality trials in the future."

Clinical • Journal • Retrospective data • Review • Cardiovascular • CNS Disorders

Implications of GPIIB-IIIA Integrin and Liver X Receptor in Platelet-Induced Compression of Ovarian Cancer Multi-Cellular Spheroids. (PubMed, Cancers (Basel)) - " Eptifibatide, a GPIIB-IIIA integrin inhibitor, and dipyridamole, an adenosine reuptake inhibitor, reduced and enhanced platelet effects on ovarian cancer spheroids, respectively. Integrin pathways and their downstream LXR/RXR effectors are implicated in how platelets alter ovarian cancer spheroid morphology. These results support studying eptifibatide and LXR/RXR agonists as candidate drugs for repurposing as therapeutic strategies to counteract platelet promotion of ovarian cancer."

Journal • Oncology • Ovarian Cancer • Solid Tumor

The triple combination DBDx alleviates cytokine storm and related lung injury. (PubMed, Int Immunopharmacol) - "Here, we investigated the anti-cytokine storm efficacy of DBDx, a triple drug combination composed of dipyridamole, ubenimex and dexamethasone. All of these results demonstrate that DBDx, a triple combination of clinical orally-administered drugs, can alleviate cytokine storm and related lung injury. DBDx is beneficial for treating cytokine storm disorders."

Cytokine storm • Journal • Respiratory Diseases • HIF1A • IL1B • IL6 • TLR4 • TNFA

Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma (SWOG-Fall 2024) - "Participants must have progressed on prior therapy with fluoropyrimidine and/or oxaliplatin, given either for metastatic/locally advanced disease or as adjuvant therapy completed within the previous 12 months...Participants must not be receiving chronic antiplatelet therapy, including dipyridamole or clopidogrel, or similar agents...Two major protocol deviations were recorded: one participant received reduced doses of all drugs for the first cycle in error, and another participant did not receive leucovorin and fluorouracil IV bolus during the first cycle...Of the 16 participants assessed on the Ramucirumab + Paclitaxel arm, five experienced Grade 4 hematologic events. Among the 13 participants assessed on the FOLFIRI arm, one Grade 5 toxicity (Death NOS) has been reported and two participants had Grade 4 neutropenia."

Clinical • P2 data • Ampulla of Vater Carcinoma • Cardiovascular • CNS Disorders • Colorectal Cancer • Hematological Disorders • Hypertension • Metabolic Disorders • Microsatellite Instability • Musculoskeletal Diseases • Neutropenia • Oncology • Small Intestinal Carcinoma • Solid Tumor • MSI

Comparison of the Safety of Prednisone Plus Dipyridamole Versus Prednisone Plus Valsartan in the Treatment of Children with Primary Nephrotic Syndrome. (PubMed, Iran J Kidney Dis) - "Both Pred + DIP and Pred + VAL combination therapies can be used for the treatment of pediatric NS, with the former contributing to more obviously enhanced coagulation and immune functions, and the latter leading to more significantly inhibited inflammation and better regulated blood lipid function."

Clinical • Journal • Glomerulonephritis • Inflammation • Nephrology • Pediatrics • Renal Disease

Curcumin-Based Molecularly Imprinted Polymer Electropolymerized on Single-Use Graphite Electrode for Dipyridamole Analysis. (PubMed, Molecules) - "Under optimized conditions (Britton-Robinson buffer at pH = 3.29), the obtained linear ranges were 5.00 × 10-8-1.00 × 10-5 mol/L and 5.00 × 10-9-1.00 × 10-7 mol/L DIP for DPV and AdSDPV, respectively. The limits of detection of the methods were 1.47 × 10-8 mol/L for DPV and 3.96 × 10-9 mol/L DIP for AdSDPV."

Journal

Diffusion and Exchange Kinetics of Microparticle Formulations by Spatial Fourier Transform Fluorescence Recovery after Photobleaching with Patterned Illumination. (PubMed, Mol Pharm) - "To prepare microparticles for FT-FRAP analysis, a homogeneous mixture of dipyridamole and pH-independent methyl methacrylate polymer (Eudragit RS and RL) was processed using laminar jet breakup induced by vibration in a frequency-driven encapsulator...Theoretical modeling of exchange- and diffusion-controlled release revealed that both RL and RS microparticles exhibited similar exchange decay rates, but RL displayed a significantly higher diffusion coefficient. This difference in diffusion within RL and RS microparticles was correlated with their macroscopic dissolution performance."

Journal • Gastrointestinal Disorder

PULSES AND PUZZLES: REGADENOSON'S CURIOUS ENCOUNTER WITH LEFT BUNDLE BRANCH BLOCK IN MYOCARDIAL PERFUSION IMAGING (CHEST 2024) - "INTRODUCTION: Myocardial perfusion imaging (MPI) stress test is conducted utilizing exercise or vasodilatory agents such as dipyridamole, which achieves vasodilation by inhibiting adenosine deaminase and phosphodiesterase, or Regadenoson, which enhances coronary blood flow by acting as an adenosine receptor agonist, thus simulating the effects of exercise. While the exact mechanism of LBBB induced by regadenoson remains unclear, physicians should uphold clinical vigilance to exclude obstructive coronary artery disease through coronary angiography."

Cardiomyopathy • Cardiovascular • Coronary Artery Disease • Heart Failure • ADORA2A

Reduction of Coronary Flow Velocity Reserve as the Main Driver of Prognostically Beneficial Coronary Revascularization. (PubMed, J Am Soc Echocardiogr) - "In patients with CCS and physiologically and anatomically significant LAD disease, coronary revascularization driven by a reduction in CFVR is accompanied by a prognostic benefit independently of the presence of inducible RWMA."

Journal • Cardiovascular • Coronary Artery Disease

Assessment of in Vivo Performance of Lipid-Based Formulations: Correlation between in Vitro Drug Release Profiles and in Vivo Absorption Rate Profiles. (PubMed, Biol Pharm Bull) - "The type IIIA-MC (medium-chain) and type IIIA-LC (long-chain) formulations containing a Biopharmaceutics Classification System (BCS) Class II drug (dipyridamole or ketoconazole) were used as model LBFs. Overall, the profiles of in vitro free concentrations were consistent with those of in vivo absorption rates for both drugs and all LBFs. These findings would help predict the in vivo performance and establish an in vitro-in vivo correlation (IVIVC) of LBFs."

Journal • Preclinical

Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline. (PubMed, J Clin Sleep Med) - "The following recommendations are intended as a guide for clinicians in choosing a specific treatment for RLS and PLMD in adults and children. Each recommendation statement is assigned a strength ("Strong" or "Conditional"). A "Strong" recommendation (i.e., "We recommend…") is one that clinicians should follow under most circumstances. The recommendations listed below are ranked in the order of strength of recommendations and grouped by class of treatments within each PICO question. Some recommendations include remarks that provide additional context to guide clinicians with implementation of this recommendation."

Clinical guideline • Journal • Chronic Kidney Disease • Movement Disorders • Nephrology • Obstructive Sleep Apnea • Pediatrics • Renal Disease • Respiratory Diseases • Restless Legs Syndrome • Sleep Disorder

Routine clinical reproducibility of myocardial blood flow measurements with 15O-water PET (EANM 2024) - "Previous studies have shown that whole-myocardium hyperemic MBF measurement with 82Rb has a repeatability coefficient (RC) of 50% (1.3 mL/g/min) for a two-day test-retest using adenosine in healthy controls1 and 21% (0.51 mL/g/min) and 38% (0.90 mL/g/min) for a single-session and two-day test-retest using dipyridamole, respectively, in patients in clinical routine2... Automated data analysis and use of modern PET scanners results in a large improvement of reproducibility of hyperemic MBF measurements with 15O-water. Reproducibility of hyperemic MBF with 15O-water is superior to previously published values for 82Rb."

Clinical • Cardiovascular

A deep learning-based automatic segmentation method on left ventricle in dynamic myocardial perfusion using a CZT-SPECT (EANM 2024) - "Materials and The training set comprised 466 patients who underwent dipyridamole 99mTc-MIBI dynamic CZT-SPECT, and the static and dynamic external validation sets included 54 patients with manual labeling for static images and the averages of the last 180-sec of dynamic images... This study demonstrated that automatic 3D segmentation of dynamic image of LV could be effectively attained by non-rigidly registering the myocardium segmented from the static SPECT on to the mean dynamic images."

Higher Precision and Processing Repeatability of Myocardial Blood Flow and Flow Reserve Calculated Using Net Retention Model Compared to One Compartment Model in 99mTc-MIBI CZT SPECT studies (EANM 2024) - "SPECT study was carried out using a twoday rest-stress (dipyridamole) protocol with 592 MBq of 99mTc-MIBI administered each day... Repeatability of MBF and MFR values based on dynamic SPECT data calculated using RET model are better compared to 1CM model. Improved automatic positioning of heart images in 4DM v2024 significantly improved their processing repeatability. There is still a need for better standardization of dynamic SPECT MFR study processing methodology."

Cardiovascular • Coronary Artery Disease

Role of coronary artery calcium score in the detection of silent myocardial ischemia in diabetic patients with high cardiovascular risk. (EANM 2024) - "These patients benefited from a quantification of the CAC score by CT scan and then searching for SMI by Sestamibi-99mTechnetium myocardial perfusion scintigraphy (MPS) after physical stress or under dipyridamole... Searching for SMI in diabetic patients with high CV risk using the CAC score presents an insufficient sensitivity but a satisfactory negative predictive value, useful in screening situations."

Clinical • Cardiovascular • Diabetes • Metabolic Disorders • Myocardial Ischemia

Dipyridamole-Grafted Copolymer Electrospun Nanofiber Membranes for Suppression of Peritendinous Adhesions. (PubMed, Acta Biomater) - "Our experiments showed that implantation of PLC-DP was effective in reducing tissue adhesions by 47% without affecting tendon healing. We elucidated the mechanism behind this phenomenon, suggesting that PCD activates FXYD2 to inhibit TGF-β-induced expression of Col III, which is a key factor in PA development."

Journal • SMAD3 • TGFB1

Advancing the Harmonization of Biopredictive Methodologies through the Product Quality Research Institute (PQRI) Consortium: Biopredictive Dissolution of Dipyridamole Tablets. (PubMed, Mol Pharm) - "The consortium project will be accomplished in five phases, whereby the first two phases have already been completed and published. In this paper, the next two phases are addressed by reporting the biorelevant dissolution profiles of dipyridamole, a weak base model drug, then incorporating the dissolution results into physiologically based biopharmaceutics modeling (PBBM) to determine whether they would lead to bioequivalence (BE) or non-BE."

Harmonization • Journal